The road to competitive generic drug prices in Canada

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 13, 2013, Pages 1141-1144

  Law, Michael R ^a   Kratzer, Jillian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; CANADA; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; LICENSING; PATENT; PHARMACY; PURCHASING; REIMBURSEMENT;

EID: 84875506741     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121367     Document Type: Article

References (25)

1. Health Care Innovation Working Group. From innovation to action: the first report of the Health Care Innovation Working Group. Ottawa (ON): The Council of the Federation; 2012. Available: www.councilofthefederation. ca/pdfs/Health%20 Innovation %20Report-E-WEB.pdf (accessed 2012 July 26).
2. Drivers of prescription drug spending in Canada. Ottawa (ON): Canadian Institute for Health Information; 2012. Available: www.cihi.ca/CIHI-ext-portal/ pdf/internet/DRUG-SPEND-DRIVERS-EN (accessed 2012 July 24).
3. The role of the generic pharmaceutical industry in Canadian health - 2011. Toronto (ON): Canadian Generic Pharmaceutical Association; 2012. Available: www.canadiangenerics.ca/en/advocacy/docs/ The%20Role%20of%20the%20Generic% 20 Pharma ceutical %20Industry%20in%20Canadian % 20 Health % 20Care-2011.pdf (accessed 2012 July 23).
4. Lexchin J. Pharmaceuticals, patents, and politics: Canada and Bill C-22. Int J Health Serv 1993;23:147-60.
5. Smith M. Patent protection for pharmaceutical products (BP354e). Ottawa (ON): Library of Parliament/Parliamentary Research Branch; 1993. Available: http://publications.gc.ca/Collection-R/LoPBdP/BP/bp354-e.htm (accessed 2012 July 17).
6. Lexchin J. Effect of generic drug competition on the price of prescription drugs in Ontario. CMAJ 1993;148:35-8.
7. Anis AH, Guh D P, Woolcott J. Lowering generic drug prices: less regulation equals more competition. Med Care 2003;41:135-41.
8. Morgan S, Hanley G, Mcmahon M, et al. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthc Policy 2007;3:e121-40.
9. Generic drugs in Canada: international price comparisons and potential cost savings. Ottawa (ON): Patented Medicine Prices Review Board; 2011. Available: www.pmprb-cepmb.gc.ca/CMFiles/Publications/Analytical%20Studies/ NPDUIS-GenericDrugs-IPCs-e-sept30.pdf (accessed 2012 July 15).
10. Generic Drug Sector Study. Ottawa (ON): Competition Bureau; 2007. Available: http://competitionbureau.gc.ca/eic/site/cb-bc.nsf/eng/02495.html (accessed 2012 July 15).
11. Lewis S. Ontario generic drug wars, part 1: how it all began. Toronto (ON): Longwoods Publishing Corporation; 2010. Available: www.longwoods.com/ content/21910 (accessed 2012 July 18).
12. Benefiting from generic drug competition in Canada: the way forward. Ottawa (ON): Competition Bureau Canada; 2008. Available: http:// competitionbureau.gc.ca/eic/site/cb-bc.nsf/eng/02753.html (accessed 2012 July 15).
13. Law MR. Money left on the table: generic drug pricing in Canada [working paper]. Vancouver (BC): UBC Centre for Health Services and Policy Research; 2012. Available: www.chspr.ubc.ca/pubs/working-papers/money-left-table-generic- drug-prices-canada (accessed 2012 Sept. 23).
14. PharmaCare formulary search. Vancouver (BC): British Columbia Ministry of Health; 2012. Available: www.health.gov. bc.ca/pharma care/benefitslookup/ faces/Search.jsp (accessed 2012 Oct. 10).
15. Silversides A. Provincial experiments aim to lower public drug plan costs. CMAJ 2009;181:E80-2.
16. Hollis A. Generic drug pricing and procurement: a policy for Alberta. Calgary (AB): University of Calgary, School of Policy Studies; 2009. Available: http://policyschool.ucalgary.ca/files/publicpolicy/ Hollis%20ONLINE%20%28Feb%2009%29.pdf (accessed 2012 July 15).
17. Reiffen D, Ward MR. Generic drug industry dynamics. Review of Economics and Statistics 2005;87:37-49.
18. Ontario public drug programs competitive agreements: briefng for stakeholders. Toronto (ON): Ontario Ministry of Health; 2008. Available: www.health.gov. on. ca/english/providers/program/drugs/opdp-eo/notices/ stakeholder-briefing.pdf (accessed 2012 July 11).
19. Law MR, Dijkstra A, Douillard J, et al. Geographic accessibility of community pharmacies in Ontario. Healthc Policy 2011;6:36-46.
20. Standing Committee on Health. Drug supply in Canada: a multi-stakeholder responsibility. Ottawa (ON): Canadian House of Commons; 2012.
21. Managing medicine supply. Wellington (NZ): New Zealand Pharmaceutical Management Agency; 2011. Available: www.pharmac.govt.nz/2011/09/16/07MANAGING- SUPPLY.pdf (accessed 2012 Apr. 17).
22. Gagnon M-A. Drug shortages: searching for a cure. Healthc Policy 2012;7:10-7.
23. Annual review 2009. Wellington (NZ): Pharmaceutical Management Agency; 2009. Available: www.pharmac.govt.nz/2009/10/28/Annual%20Report%20- %20year%20ended%2030%20June%202009.pdf (accessed 2012 Aug. 12).
24. Law MR, Morgan SG. Purchasing prescription drugs in Canada: hang together or hang separately. Healthc Policy 2011;6:22-6.
25. Law MR, Cheng L, Dhalla IA, et al. The effect of cost on adherence to prescription medications in Canada. CMAJ 2012;184:297-302.